Unfavorable early-stage Hodgkin lymphoma: assessment of patient characteristics in a real-world setting

被引:1
作者
Gautam, Santosh [1 ]
Yeola, Shweta [1 ]
Nahar, Akash [2 ]
Sarpong, Eric M. [2 ]
Prescott, Jennifer [2 ]
Yang, Xiaoqin [2 ]
Sineshaw, Helmneh M. [2 ]
机构
[1] ConcertAI, Cambridge, MA 02138 USA
[2] Merck & Co Inc, Rahway, NJ 07065 USA
关键词
Hodgkin lymphoma; real-world data; retrospective study; unfavorable factors; OLDER PATIENTS; ADRIAMYCIN; BLEOMYCIN; OUTCOMES; ABVD;
D O I
10.2217/fon-2022-0963
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Unfavorable prognostic factors among classical Hodgkin lymphoma (cHL) patients in the real-world setting have yet to be fully characterized. Methods: In this retrospective study using the ConcertAI Oncology Dataset, patient characteristics, unfavorable prognostic factors and treatment patterns were evaluated among patients diagnosed with cHL. Results: Among 324 adult cHL patients diagnosed 2016-2021, 16.1% were classified as early favorable, 32.7% early unfavorable and 51.2% advanced disease. Early unfavorable patients were younger and had a larger nodal mass. The prognostic factor B symptoms was most frequently documented in early unfavorable patients (59.4%), followed by bulky disease (46.2%), >3 involved lymph node regions (31.1%), and erythrocyte sedimentation rate >= 50 (25.5%). Conclusion: In this analysis of real-world data, we found that nearly a third of newly diagnosed cHL patients had early unfavorable disease. Our analysis also showed differences in the proportion of patients for each unfavorable factor among patients with early-stage unfavorable cHL. Plain language summary - Assessment of risk factors in patients with classical Hodgkin lymphoma in a real-world setting What is this article about?Lymphoma is a type of blood cancer that develops when white blood cells grow out of control. This study looked at a certain type of lymphoma called classical Hodgkin lymphoma (cHL). Patients with cHL are put into groups based on risk factors. Risk factors mean the cancer had certain characteristics that make it more likely to spread to other body parts and more difficult to treat. These can be symptoms like drenching night sweats, unexplained fever, sudden weight loss, or large swellings of the infection fighting glands of the body. What did we do?We studied the risk factors of patients with cHL, using data from electronic medical records. What were the results?About a third of the patients in this study had early stage cHL with unfavorable risk factors, and over half of the patients had advanced stage cHL. The patients who had early stage cHL with unfavorable risk factors were younger and had a larger lump in a lymph node. More than half of the patients experienced drenching night sweats, unexplained fever, or weight loss of more than 10%. What do the results mean?We found that nearly a third of new cHL patients had early-stage cHL with unfavorable risk factors. We also showed differences in the number of patients with each unfavorable risk factor among patients with early-stage unfavorable cHL. This study can help doctors and researchers group patients and determine the best treatment or research study for patients who have cHL.
引用
收藏
页码:1249 / 1259
页数:11
相关论文
共 18 条
  • [1] The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor†
    Andersen, Maja D.
    Kamper, Peter
    d'Amore, Alexander
    Clausen, Michael
    Bentzen, Hans
    d'Amore, Francesco
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 927 - 933
  • [2] [Anonymous], 2022, REFERENCED PERMISSIO
  • [3] A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
    Ballova, V
    Rüffer, JU
    Haverkamp, H
    Pfistner, B
    Müller-Hermelink, HK
    Dühmke, E
    Worst, P
    Wilhelmy, M
    Naumann, R
    Hentrich, M
    Eich, HT
    Josting, A
    Löffler, M
    Diehl, V
    Engert, A
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (01) : 124 - 131
  • [4] ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials
    Boell, Boris
    Goergen, Helen
    Fuchs, Michael
    Pluetschow, Annette
    Eich, Hans Theodor
    Bargetzi, Mario J.
    Weidmann, Eckhart
    Junghanss, Christian
    Greil, Richard
    Scherpe, Alexander
    Schmalz, Oliver
    Eichenauer, Dennis A.
    von Tresckow, Bastian
    Rothe, Achim
    Diehl, Volker
    Engert, Andreas
    Borchmann, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (12) : 1522 - 1529
  • [5] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [6] Cheng J., COTSWOLDS MODIFIED A
  • [7] Prognostic Factors in Hodgkin Lymphoma
    Cuccaro, Annarosa
    Bartolomei, Francesca
    Cupelli, Elisa
    Galli, Eugenio
    Giachelia, Manuela
    Hohaus, Stefan
    [J]. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01): : 1 - 10
  • [8] The efficacy-toxicity conundrum: breaking the mold
    Diehl, Louis F.
    [J]. BLOOD, 2020, 135 (10) : 704 - 706
  • [9] The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
    Evens, Andrew M.
    Hong, Fangxin
    Gordon, Leo I.
    Fisher, Richard I.
    Bartlett, Nancy L.
    Connors, Joseph M.
    Gascoyne, Randy D.
    Wagner, Henry
    Gospodarowicz, Mary
    Cheson, Bruce D.
    Stiff, Patrick J.
    Advani, Ranjana
    Miller, Thomas P.
    Hoppe, Richard T.
    Kahl, Brad S.
    Horning, Sandra J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) : 76 - 86
  • [10] Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
    Halbsguth, Teresa V.
    Nogova, Lucia
    Mueller, Horst
    Sieniawski, Michal
    Eichenauer, Dennis A.
    Schober, Thomas
    Nisters-Backes, Hiltrud
    Borchmann, Peter
    Diehl, Volker
    Engert, Andreas
    Josting, Andreas
    [J]. BLOOD, 2010, 116 (12) : 2026 - 2032